Related Experiment Video

Updated: Sep 20, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

[Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol]

M Iu Sitnikova, E V Shliakhto

    Klinicheskaia Meditsina
    |August 26, 2003
    PubMed

    Insights

    Carvedilol improved chronic cardiac failure (CCF) symptoms and exercise tolerance in patients. This beta-blocker also showed an endothelioprotective effect, reducing inflammation and improving endothelial function.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Vascular Biology

    Background:

    • Chronic cardiac failure (CCF) significantly impacts patient quality of life and prognosis.
    • Endothelial dysfunction is a key component in the pathophysiology of CCF.
    • Beta-blockers are a cornerstone of CCF management, but their specific effects on endothelial function require further elucidation.

    Purpose of the Study:

    • To evaluate the effects of carvedilol, a beta-adrenoblocker, compared to placebo in patients with severe CCF (functional classes III-IV).
    • To assess carvedilol's impact on clinical outcomes, exercise tolerance, and endothelial function markers.
    • To investigate the dose-dependent effects of carvedilol on endothelial and inflammatory markers.

    Main Methods:

    • A 6-month, open-label, randomized trial involving 60 CCF patients.
    • Patients received carvedilol in addition to standard therapy (ACE inhibitors, diuretics, cardiac glycosides).
    • Evaluated clinical course, 6-minute walk test, endothelium-dependent vasodilation, circulating endotheliocytes, triglycerides, malonic dialdehyde, IL-8, and uric acid levels.

    Main Results:

    • Carvedilol treatment showed a trend towards reduced hospitalizations and improved CCF symptoms.
    • Patients on carvedilol exhibited better exercise tolerance and lower levels of uric acid, malonic dialdehyde, and IL-8.
    • A trend towards improved brachial artery diameter and reduced endotheliocyte circulation was observed with carvedilol, particularly at doses of 25-50 mg/day.

    Conclusions:

    • Long-term treatment with standard doses of carvedilol in CCF patients improves clinical status.
    • Carvedilol demonstrates a significant endothelioprotective effect, reducing inflammation and improving endothelial function.
    • The findings support the inclusion of carvedilol in the management of severe CCF for both clinical and vascular benefits.

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.